This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
In a randomized, double-blind, placebo-controlled, phase 3 trial of patients at high risk of recurrent advanced RCC following nephrectomy1
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2025 Pfizer Inc. All rights reserved.
SUTENT® (sunitinib malate) is indicated for: